Fig. 4

Cell viability assay with MTT. Evaluation of IC50 of CP (a), IC50 of CP loaded NPs (b), and comparison of IC50 and IC80 of bare CP and CP loaded NPs (c). Cell viability assay measurements in malignant PBMCs and BMMCs after both 24 (Horizontal line bars represent the mean in each treatment group, and mean of PBMCs = 64.08 and mean of BMMCs = 64.36) (d) and 48 h (Horizontal line bars represent the mean in each treatment group, and mean of PBMCs = 49.57 and mean of BMMCs = 50.10) (e) of treatment with different combination therapies is also shown. BrdU incorporation was used to assess the effect of anti-Nrf2 siRNA and CP codelivery on cancer cell proliferation (Horizontal line bars represent the mean in each treatment group, and mean of PBMCs = 60.33 and mean of BMMCs = 59.89, error bars above and below show the mean with SD) (f). The data corresponding to the primary PBMCs and BMMCs samples obtained from CLL patients are demonstrated as means of individual patient experiments (n = 10). P-values < 0.05 (*), P-values < 0.01 (**), P-values < 0.001 (***) and P-values < 0.0001 (****)